Quantcast
Last updated on April 23, 2014 at 15:23 EDT

Latest Sunovion Stories

2014-04-15 12:29:59

PITTSBURGH, April 15, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Eszopiclone Tablets 1 mg, 2 mg and 3 mg, the generic version of Sunovion Pharmaceuticals Inc.'s Lunesta(®). Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of insomnia. Eszopiclone Tablets 1 mg, 2 mg, 3 mg had U.S. sales of approximately $851.8...

2014-03-19 16:23:40

ALISO VIEJO, Calif., March 19, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the appointment of Dr. Mark Corrigan to the company's board of directors. Dr. Corrigan, a seasoned life sciences executive joins Avanir's board with broad healthcare industry experience. http://photos.prnewswire.com/prnvar/20130207/LA55901LOGO Dr. Corrigan currently serves as president and chief executive officer of Zalicus Inc. a public biopharmaceutical company, a...

2013-10-14 23:20:31

Reportbuyer.com just published a new market research report: Global Pulmonary Drug Delivery Systems Market 2012-2016. London (PRWEB) October 14, 2013 TechNavio's analysts forecast the Global Pulmonary Drug Delivery Systems market to grow at a CAGR of 14.47 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing incidence of lung-related or respiratory diseases. The Global Pulmonary Drug Delivery Systems market has also been...

2013-09-18 08:30:03

MISSISSAUGA, ON, Sept. 18, 2013 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today announced that Health Canada has accepted for review the company's New Drug Submission (NDS) for eslicarbazepine acetate for use as a once-daily adjunctive therapy in the treatment of partial-onset seizures in patients 18 years of age and older with epilepsy. The efficacy and safety of eslicarbazepine acetate as an adjunctive or monotherapy treatment for partial-onset seizures in adults...

2013-07-08 12:28:07

PITTSBURGH, July 8, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that the U.S. District Court for the Southern District of New York has issued a Final Judgment and Order following a ruling by the Court of Appeals for the Federal Circuit in favor of Mylan Specialty L.P., f/k/a Dey Pharma, L.P. The Order states that five of Mylan's patents related to its Perforomist® Inhalation Solution are valid and enforceable. Further, the Order states that Sunovion's Brovana®...

2013-03-26 20:22:30

NASDAQ: CRME TSX: COM VANCOUVER, March 26, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME) (TSX:COM) today announces changes to the company's senior management team. William Hunter, M.D., previously interim Chief Executive Officer and Director, has been appointed full time President and Chief Executive Officer;  Karim Lalji has been promoted from Senior Vice President of Commercial Affairs to Chief Commercial Officer; and Sheila Grant has been hired as Chief Operating...

2013-03-18 12:28:30

PITTSBURGH, March 18, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate). This product is the generic version of Sunovion's Xopenex(® )Inhalation Solution, which is indicated for the...

2013-02-12 08:29:43

REDWOOD CITY, Calif., Feb. 12, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the appointment of Adrian Adams, Chief Executive Officer and President of Auxilium Pharmaceuticals, Inc., to its Board of Directors (Board) as Chairman of the Board. Thomas Schreck, co-founder of AcelRx and Board...